Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2016

View Archived Issues

Phase II results demonstrate safety and efficacy of new drug for Wilson's disease

Oyi-based therapeutic HIV vaccine reduces the HIV RNA rebound median following cART interruption

TGI and Quark enter discovery and development collaboration

Zavante starts ZEUS trial for ZTI-01 in cUTI patients

KU Leuven and Ortho-McNeil-Janssen Pharmaceuticals patent dengue viral replication inhibitors

Oncolytics reports results on Reolysin phase II study

Akari and XL-protein to develop longer-acting version of Coversin

Synta Pharmaceuticals and Madrigal Pharmaceuticals announce merger agreement

RespiVert and Topivert Pharma disclose MAPK14, Src and Syk inhibitors

Redx Pharma develops IDO1 and/or TDO2 inhibitors

XuanZhu Pharma describes ALK and MCF3 inhibitors

Merrimack and Leica partner to develop companion diagnostic assays

PI3K inhibitors revealed in XuanZhu Pharma patent

Presage extends alliance with Takeda to provide access to CIVO platform

Burzynski Research Institute initiates phase II trial in diffuse intrinsic brainstem glioma

GeoVax receives SBIR grant for clade B HIV vaccine

TGen announces two new combination trials in pancreatic cancer

FDA acepts sBLA for Opdivo in patients with classical Hodgkin lymphoma

PsiOxus and Parker Institute collaborate on T-sign cancer platform

USAID launches Combating Zika and Future Threats: A Grand Challenge for Development

Phase I/IIa study investigates topically applied bisphosphocin Nu-3 for diabetic ulcers

FBRI and Meiji Seika collaborate on autoimmune and cancer drug research

Promising HCV T-cell vaccine HCV-003 to advance to phase II trials

Novel mutation in USMG5 gene may cause Leigh syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...